Document is current

Article History

Received: 7 December 2024

Accepted: 3 March 2025

First Online: 11 March 2025

Competing interests

: No funding was provided for this study. Individual disclosures for co-authors are as noted below:Y. B reports honoraria for lectures from Stemline, Lilly, Roche, Gilead, Pfizer, Novartis; and consulting/advisory role for Lilly, Novartis. L.W.E reports consulting/advisory role for Mersana Therapeutics, Kisoji Biotech and Astra Zeneca. L.M.S reports consultant/advisory role for Novartis, Daiichi Pharma, Astra Zeneca, Eli Lilly, Precede, Seagen; institutional research support from Merck, Genentech, Gilead, Eli Lilly, Astra Zeneca; and travel support from Eli Lilly. S.A.W reports consulting/advisory role for Foundation Medicine, Veracyte, Hologic, Eli Lilly, Biovica, Pfizer/Arvinas, Puma Biotechnology, Novartis, AstraZeneca, Genentech, Regor Therapeutics, Menarini; education/speaking fees from Eli Lilly, Guardant Health, 2ndMD; and institutional research support from Genentech, Eli Lilly, Pfizer/Arvinas, Nuvation Bio, Regor Therapeutics, Sermonix. N.V reports research funding to the institution (MGH) from Merck, Daehwa, Novartis, Pfizer, Radius, Stemline, Ellipses; and advisory board participation (all ended) for AbbVie, OncoSec, Gilead, Aadi, TerSera, Novartis, IDEOlogy Health. A.B. reports consulting or advisory Role for Pfizer, Novartis, Genentech, Merck & Co., Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/AstraZeneca, Phillips, Eli Lilly and Foundation Medicine and research/grant (to institution) from Genentech, Novartis, Pfizer, Merck & Co., Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/AstraZeneca and Eli Lilly. The remaining authors declare no competing interests.